StockNews.com Initiates Coverage on Brainstorm Cell Therapeutics (NASDAQ:BCLI)

StockNews.com assumed coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a research note issued to investors on Tuesday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Separately, Maxim Group upgraded Brainstorm Cell Therapeutics from a hold rating to a buy rating and set a $2.00 target price on the stock in a research note on Thursday, July 11th.

Brainstorm Cell Therapeutics Price Performance

BCLI opened at $2.33 on Tuesday. The firm has a market cap of $163.29 million, a PE ratio of -6.94 and a beta of 0.33. The stock has a 50-day moving average price of $0.44 and a 200-day moving average price of $0.46. Brainstorm Cell Therapeutics has a 1 year low of $2.01 and a 1 year high of $11.89.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last issued its earnings results on Wednesday, August 14th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.04). During the same quarter in the prior year, the company posted ($0.27) earnings per share. As a group, sell-side analysts anticipate that Brainstorm Cell Therapeutics will post -0.19 EPS for the current year.

Hedge Funds Weigh In On Brainstorm Cell Therapeutics

An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Armistice Capital LLC acquired a new stake in shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 7,917,653 shares of the biotechnology company’s stock, valued at approximately $2,680,000. Armistice Capital LLC owned about 11.30% of Brainstorm Cell Therapeutics as of its most recent SEC filing. Institutional investors own 14.33% of the company’s stock.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.